Edition:
United States

Applied DNA Sciences Inc (APDN.OQ)

APDN.OQ on NASDAQ Stock Exchange Capital Market

1.42USD
21 Sep 2018
Change (% chg)

$0.03 (+2.16%)
Prev Close
$1.39
Open
$1.47
Day's High
$1.52
Day's Low
$1.40
Volume
56,783
Avg. Vol
12,782
52-wk High
$3.45
52-wk Low
$1.10

Latest Key Developments (Source: Significant Developments)

Applied DNA Forms Subsidiary, Linearx
Tuesday, 18 Sep 2018 07:14am EDT 

Sept 18 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA FORMS WHOLLY OWNED SUBSIDIARY, LINEARX, TO DEVELOP LARGE-SCALE, PCR-PRODUCED DNA FOR BIOTHERAPEUTICS.APPLIED DNA SCIENCES - PURPOSE OF NEW UNIT TO COMMERCIALIZE CO'S DESIGN, MANUFACTURE AND CHEMICAL MODIFICATION OF DNA.APPLIED DNA - LINEARX WILL ALSO SUBSUME CURRENT ACTIVITIES OF CO AS A CRO AND CMO TO BIOTHERAPEUTICS MARKET.  Full Article

Applied DNA Signs Agreements With Colorcon For Molecular Tagging In Pharmaceutical, Nutraceutical Markets
Thursday, 5 Apr 2018 05:00am EDT 

April 5 (Reuters) - Applied DNA Sciences Inc ::APPLIED DNA SIGNS DEFINITIVE AGREEMENTS WITH COLORCON FOR MOLECULAR TAGGING IN THE PHARMACEUTICAL AND NUTRACEUTICAL MARKETS.AGREEMENTS INCLUDES MILESTONE PAYMENTS. LONG-TERM LICENSING ROYALTIES TO BE PAID TO APPLIED DNA FOLLOWING SALES..‍FIRST OF TWO MILESTONE PAYMENTS IS PAYABLE TO APPLIED DNA WITH SIGNING OF AGREEMENTS​.‍TO GET SECOND MILESTONE PAYMENT ON INITIAL APPROVAL BY REGULATORY AUTHORITY FOR APPLICATION IN SOD PHARMACEUTICAL OR NUTRACEUTICAL PRODUCT APPLICATION.WILL SUPPLY TAGGANT AND AUTHENTICATION MATERIALS TO COLORCON IN EXCHANGE FOR LONG-TERM ROYALTIES.AGREEMENTS GENERALLY EXPIRE ON LATER OF OCTOBER 1, 2032 OR LAST EXPIRATION DATE OF ANY PATENT LICENSED UNDER AGREEMENT​.  Full Article

Applied DNA Reports Q1 Loss Per Share $0.12
Thursday, 8 Feb 2018 04:05pm EST 

Feb 8 (Reuters) - Applied Dna Sciences Inc ::APPLIED DNA REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.12.Q1 REVENUE FELL 28 PERCENT TO $648,000.SEES FY 2018 REVENUE $6.5 MILLION.  Full Article

Double Medical Technology unit obtains high-tech enterprise recognition
Wednesday, 7 Feb 2018 10:56pm EST 

Feb 8(Reuters) - Double Medical Technology Inc <002901.SZ> ::Says its unit recognized as high-tech enterprise .Says its unit will enjoy tax preference of 15 percent for three years from Dec. 1, 2017 .  Full Article

Applied DNA Sciences Establishes New Central DNA Testing Laboratory In India
Tuesday, 23 Jan 2018 05:30am EST 

Jan 23 (Reuters) - Applied Dna Sciences Inc ::APPLIED DNA SCIENCES INC SAYS HAS ESTABLISHED A CENTRAL DNA TESTING LABORATORY IN AHMEDABAD, INDIA, PROVIDING FULL FORENSIC AUTHENTICATION SERVICES.  Full Article

Wuhan Thalys Medical Technology and partner jointly sign contract with Pingdu People's Hospital
Monday, 8 Jan 2018 01:07am EST 

Jan 8(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says it and China Resources Shandong Pharmaceutical Co Ltd jointly signed contract with Pingdu People's Hospital, regarding centralized purchasing and supply of test reagent and consumable.  Full Article

Wuhan Thalys Medical Technology signs contracts with Wuhan Hospital of Traditional Chinese Medicine
Monday, 8 Jan 2018 12:59am EST 

Jan 8(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says it signed contracts with Wuhan Hospital of Traditional Chinese Medicine, regarding centralized delivery of test reagent and consumable.  Full Article

Applied DNA Sciences Q4 Revenue $1.1 Million
Thursday, 28 Dec 2017 04:05pm EST 

Dec 28 (Reuters) - Applied Dna Sciences Inc ::APPLIED DNA SCIENCES REPORTS YEAR END AND FISCAL FOURTH QUARTER RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE FELL 30 PERCENT TO $1.1 MILLION.  Full Article

Wuhan Thalys Medical Technology unit sets up medical tech unit in Tai'an City
Tuesday, 19 Dec 2017 04:51am EST 

Dec 19(Reuters) - Wuhan Thalys Medical Technology Inc <603716.SS>:Says co's Jinan-based medical technology unit sets up a wholly owned medical technology unit in Tai'an City, with registered capital of 10 million yuan .  Full Article

Applied DNA And Colorcon To Collaborate To Commercialize Product Authentication Technology
Monday, 18 Dec 2017 05:30am EST 

Dec 18 (Reuters) - Applied Dna Sciences Inc ::APPLIED DNA AND COLORCON ANNOUNCE COLLABORATION TO COMMERCIALIZE PRODUCT AUTHENTICATION TECHNOLOGY FOR PHARMACEUTICAL AND NUTRACEUTICAL INDUSTRY.APPLIED DNA SCIENCES INC - CO, COLORCON INC HAVE ENTERED INTO A TECHNOLOGY LICENSE MEMORANDUM OF UNDERSTANDING.APPLIED DNA SCIENCES - DEAL TO COMMERCIALIZE PLATFORM FOR TRACEABILITY DIRECTLY ON DOSE, IS INTENDED TO REDUCE RISKS ASSOCIATED WITH COUNTERFEIT MEDICATIONS.  Full Article

BRIEF-Applied DNA Reports Q2 Loss Per Share Of $0.07

* APPLIED DNA REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS